CGM = continuous glucose monitor(ing)
The #1 CGM brand in the US†
Discreet6
The world's smallest sensor§6 is worn discreetly on the back of your upper arm.
Affordable
More people pay $0 for FreeStyle Libre systems than any other CGMs‡6.
No fingersticksII¶
All it takes is a quick glance at a smartphone# to check glucose levels.
What is CGM?
Continuous glucose monitors, like the FreeStyle Libre family of products, are small sensor-based systems that provide glucose readings day and night**, without fingersticksII¶.
Easily see patterns in your readings to learn how food, activity, and insulin impact your glucose.
Real-time glucose readings with a glance at your smartphone#
Download the Libre app today!
Before you can use your smartphone for sensor readings, you’ll need to download the Libre app. Check to see if your smartphone is compatible here.
Use your camera to scan the QR code and download the app!
Get guided support with MyFreeStyle.
When you request your free†† sensor, you will also receive free tips and tools via email and optional text messages.
Easy tutorials for applying, starting, checking, and interpreting your sensor readings on your smartphone#.
See how meals and activity affect your glucose.
Get tips for when your glucose is heading up or down, so you can treat early.
If you are commercially insured or cash paying, you may qualify for a free†† sensor.
Real people, real differences
“For anybody that's newly living with diabetes or who has been living with diabetes for a while, don't be afraid to make the changes.”
- Jeniese
“My advice to people living with diabetes is to be proactive in your journey towards good health. If you come across a hurdle, stand up for yourself because you're worth it.”
- Dawn
“I wasn’t managing my diabetes well because I wasn’t doing the fingersticks||¶. And now, the FreeStyle Libre 3 Plus sensor is applied to the back of my arm, I pull my smartphone# out, I check my readings, and off we go.”
- Sean
The views expressed should not be used for medical diagnosis or treatment or as a substitute for professional medical advice. Individual symptoms, situations and circumstances may vary.
The FreeStyle Libre 14 day Flash Glucose Monitoring System is indicated for the management of diabetes in persons aged 18 and older.
The FreeStyle Libre 3 system and FreeStyle Libre 2 system are indicated for use in people with diabetes age 4 and older.
Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.
* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
† Based on retail and durable medical equipment (DME) sales data for patient’s last-filled prescription, by manufacturer.
‡ Based on prescription claims for the aggregate of patients covered by Commercial insurance, Managed Medicare, Managed Medicaid using the FreeStyle Libre personal CGM systems versus competitors’ CGM systems. Does not include fee-for-service Medicare, fee-for-service Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre personal CGM systems require a prescription.
§ Among patient-applied sensors.
II FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
¶ FreeStyle Libre 2 and 3 systems: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.
# The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.
** Based on the sensor being replaced once every 14 days, and scanned at least once every 8 hours. The FreeStyle Libre 3 system does not require scanning.
†† or ♢ Eligible patients will receive one (1) FreeStyle Libre 2 Plus sensor or (1) FreeStyle Libre 3 Plus sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1 diabetes or Type 2 diabetes or gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 2 Plus sensor or (1) FreeStyle Libre 3 Plus sensor. Patients ages 2–17 are eligible to receive an offer for the (1) FreeStyle Libre 2 Plus sensor or (1) FreeStyle Libre 3 Plus sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 2 Plus sensor or (1) FreeStyle Libre 3 Plus sensor is provided as a sample and is limited to one sample per eligible person per product identification number. The FreeStyle Libre 2 Plus sensor or FreeStyle Libre 3 Plus sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.
References: 1. Fokkert, Marion, et al. "Improved Well-Being and Decreased Disease Burden After 1-Year Use of Flash Glucose Monitoring (FLARE-NL4)." BMJ Open Diabetes Research & Care 7 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 2. Evans, Mark, et al. "Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for Up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies." Diabetes Therapy 13, no. 6 (2022): 1175–1185. https://doi.org/10.1007/s13300-022-01253-9. 3. Alva, Shridhara, et al. "Accuracy of a 15-Day Factory-Calibrated Continuous Glucose Monitoring System with Improved Sensor Design." Journal of Diabetes Science and Technology (2025): 19322968251329364. https://doi.org/10.1177/19322968251329364. 4. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: A Multicentre, Open-Label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 5. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring Technology by Children and Young People with Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294–1301. https://doi.org/10.1111/pedi.12735. 6. Data on file. Abbott Diabetes Care, Inc.
ADC-12211 v39.0